<DOC>
	<DOC>NCT01681290</DOC>
	<brief_summary>The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral neuropathy (DPN).</brief_summary>
	<brief_title>Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Key Give informed consent; 1865 years old; Have type 1 diabetes mellitus for a minimum of 5 years, with a stable diabetic regimen (for at least 3 months); Have clinical signs of diabetic peripheral neuropathy at screening; Have abnormal sural nerve conduction observed bilaterally during screening; Be Cpeptide deficient; Be in good general health (besides having type 1 diabetes mellitus); Practice effective contraception during and for at least 12 weeks after study participation; Have a body mass index (BMI) ≥18.0 and &lt;35.0 kg/m2. Key Any significant cardiovascular, hematological, lymphatic, immunologic, urologic, dermatologic, psychiatric, renal, hepatic, pulmonary, endocrine (except for diabetes mellitus), central nervous, gastrointestinal, or other major disease; Unstable or inadequate glucose control; Any clinically significant laboratory value at screening; Occurrence of a severe, unexplainable hypoglycemic event (defined as requiring the assistance of another individual) within 6 months of Day 0, or recurrent episodes of nonsevere hypoglycemia (≥3 per week on average) that are deemed clinically significant by the Investigator; Have had an islet cell, kidney, and/or pancreas transplant; If female, is pregnant or lactating; History of alcohol or substance abuse within 2 years; Positive screen for hepatitis B, hepatitis C antibody, or human immunodeficiency virus (HIV) antibody; Initiation of treatment or change of dose of medication that could affect peripheral nerve function within 60 days; Previous treatment with CBX129801 or unmodified Cpeptide; Receipt of an investigational product or therapeutic device, or participation in a drug research study, within a period of 30 days; Chronic use of oral steroids or use of Ampyra (dalfampridine) within 60 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>